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1. Introduction 
Human protein tyrosine phosphatases regulate a 
number of biochemical processes which depend on 
dephosphorylation of phosphotyrosine residues in 
proteins [19, 22, 24].  
Intracellular Protein Tyrosine Phosphatase 1B 
(PTP1B) is known to be involved in insulin receptor 
dephosphorylation and considered a negative 
regulator of insulin signal transduction [9].  
It means that PTP1B is one of the most 
promising therapeutic targets for potential treatment 
of type 2 diabetes and obesity [10].  
There is constantly growing interest in 
developing inhibitors of this enzyme [24, 25].  
Derivatives of carboxylic, phosphonic, sulfonic 
acids [3, 13, 21, 26], heterocyclic and other 
compounds [11, 12] have been tested as PTP1B 
inhibitors.  
As it is known computer simulations play an 
important role in drug design.  
In the case of PTP1B such methods has been 
already applied.  
Several active compounds have been studied 
using computer-based approaches, including 
molecular docking [7, 8].  
Molecular docking is also an important tool used 
to understand detailed mechanisms of inhibitor 
binding to the enzyme [1, 15, 16, 17, 18]. 
PTP1B is a one or rare cases when the enzyme is 
represented by a large amount of data in the PDB 
data bank [2].  
This is another proof of the significance of the 
enzyme, but it also a challenge for the investigator.  
Computer simulations usually rely on multi-
dimentional optimization.  
This make them heavily dependent on starting 
conditions since the energy surfaces are very 
complicated with a great number of local minima. 
2. Analysis of publications 
The investigation of the conformations of PTP1B in 
complexes with different inhibitors has already been 
published [20]. new approach that allows 
investigation of selected parts of macromolecules 
(especially enzymes) has been proposed.  
The approach allows to study the mobility of 
selected parts of enzymes (amino acid residues in 
the active site) on the basis of X-ray images. 
Crystal structures of enzymes and mobility of 
amino acid residues of enzymes are known to serve 
as a framework for understanding the mechanism of 
enzyme catalysis and can provide a structural basis 
for the search for potent and selective inhibitors and 
obtained during, such investigation results may help 
in further understanding of enzyme functioning and 
provide starting points for the computer simulations 
of inhibitor binding. 
As it is known, molecular simulations (docking, 
molecular dynamics, even quantum chemistry) play 
an important role in drug design. 
On the other hand modeling of molecules and 
especially macromolecules is a great challenge due 
to their high complexity and flexibility.  
The results of computer simulations are highly 
dependent on starting conditions (they tend to find 
the nearest local minimum).  
This means that finding of relevant starting 
conditions is really important.  
It was also found that using one conformation of 
an enzyme is not enough to cover all possible modes 
of its interaction.  
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It was suggested to use an ensemble of starting 
conformations.  
The conformations were usually generated by 
computer and clustered [23].  
It has been already suggested to use multiple 
conformations from crystallographic sources [4].  
It was also suggested to use conformations of an 
enzyme, obtained by experimental methods, cluster 
them and use cluster centroids as an ensemble of 
starting conformations for further computer 
simulations.  
Experimental data are different from data 
obtained by computer simulations.  
In many cases they are not complete or require 
some special treatment.  
At the same time it was found in the case of 
PTP1B that conformation of a free enzyme is 
substantially different from the conformations of the 
enzyme in the enzyme-inhibitor complexes (the so 
called induced fit) [20].  
It means that experimental data (PDB) give more 
solid grounds for further investigations. 
Unfortunately there are usually only few 
structures and investigators are happy to have at 
least something to start, but in some cases (PTP1B, 
thrombin) there are a lot of structures and an 
investigator has to choose.  
PTP1B is represented by more than 100 
structures in the RSCB protein data bank.  
The PDB database is constantly growing and 
there will be more and more cases like PTP1B.  
So, the authors think that the proposed approach 
will be more demanded. 
It is not possible to use all existing crystal 
structures of enzyme for efficient screening.  
This led us to the conclusion that existing data on 
binding sites from the PDB files should be divided into 
classes based on the similarity of the binding profile. 
This can be achieved by clustering all available 
conformations.  
Centroids of clusters as representatives of 
corresponding binding modes can be used as good 
starting points for molecular simulations. 
In our case, we needed a special tool, which is 
able to compare only selected parts (active sites) of 
multiple protein structures.  
The results of clustering PTP1B conformations 
are presented in the article [20]. It was found that all 
existing conformations of the active center can be 
divided into 5 clusters (Table 1). 
It means that there are 5 typical conformation of 
PTP1B in complex with inhibitor.  
Free enzyme adopts a different conformation, 
which means that it is rather difficult to start 
simulations from it. 
The goal of this study was to investigate the 
difference between the clusters of PTP1B 
conformations by docking known PTP1B inhibitors. 
The authors decided to test this approach and try 
docking of known PTP1B inhibitors into centroids 
of all 5 clusters.  
The inhibitors were taken from the NIH database [14].  
It was assumed that all inhibitors containing 
phosphonic group should interact with the catalytic 
site of the PTP1B and their phosphonice groups 
should be located not far from Cys215.  
The database contained 208 unique compounds 
with phosphonic groups.  
In several cases there were several records with 
the same compound.  
It such cases the record with the highest pKi 
value was chosen.  
Some compounds had more than one phoshonic 
group.  
In such cases all possible ways of binding were tested.  
As a result 208 compounds gave 258 variants of 
their binding. 
Table 1. Clusters of PDB structures and distribution of the best (most similar to experimental) results between them 
Cluster Centroid  (PDB code) 
Number of 
structures 
RMSD from 
ligand-free 
conformation 
2HNP (Å) 
WPD-loop 
Number of the 
best docking 
results for the 
cluster 
1 1NL9 7 1.37 Open 24 
2 1PH0 15 1.02 Open 39 
3 2CNF 22 2.39 Closed 46 
4 1Q6M 11 2.51 Closed 48 
5 2CM8 44 2.23 Closed 48 
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Table 2. Docking results (pKi, -log10 of inhibition constant Ki) for the first 35 of 208 compounds for all clusters 
Cluster centroids 
Name 1Q6M 
R2 = 0.03 
2CM8 
R2 = 0.06 
2CNF 
R2 = 0.03 
1NL9 
R2 = 0.03 
1PH0 
R2 = 0.02 
Best 
R2 = 0.69a 
R2 = 0.76b 
Experimental 
pKi 
1_1 – – 3.271 4.818 4.356 – 8.222 
1_2 8.045 – 3.938 5.787 5.816 8.045 8.222 
2_1 3.330 4.877 – 5.845 6.659 6.659 7.921 
2_2 9.630 9.248 8.302 5.390 5.721 – 7.921 
3_1 – – – 3.982 3.462 – 8.222 
3_2 8.273 7.437 3.183 5.603 5.383 8.273 8.222 
4_1 6.755 6.263 6.703 4.195 3.814 6.263 5.770 
5_1 – – – 4.034 5.024 – 7.959 
5_2 7.517 6.271 5.684 – 3.432 7.517 7.959 
6_1 8.265 7.136 6.938 5.581 5.258 5.258 5.095 
7_1 8.463 8.302 7.261 5.244 4.716 8.302 7.796 
7_2 8.925 5.442 6.014 5.713 4.320 – 7.796 
8_1 6.703 7.033 7.591 5.310 5.478 7.591 8.770 
8_2 6.835 6.087 6.124 5.801 5.097 – 8.770 
9_1 6.571 7.283 6.322 5.706 5.677 7.283 7.337 
9_2 6.366 5.581 6.263 5.515 5.317 – 7.337 
10_1 7.327 7.173 8.016 3.124 5.170 7.327 7.377 
10_2 7.987 7.561 5.398 4.100 6.205 – 7.377 
11_1 9.945 6.857 7.686 5.691 4.628 7.686 7.638 
12_1 8.786 7.906 7.877 6.542 4.980 7.877 7.420 
13_1 9.065 6.344 6.931 5.897 5.002 – 8.523 
13_2 11.529 8.617 8.801 6.271 5.288 8.617 8.523 
14_1 6.483 4.752 5.075 4.356 4.334 – 8.000 
14_2 10.979 8.742 7.752 5.178 4.474 7.752 8.000 
15_1 – – – 3.403 5.948 – 8.301 
15_2 9.989 9.138 5.809 5.024 4.048 9.138 8.301 
16_1 5.845 5.046 6.102 5.508 4.855 – 9.398 
16_2 7.510 6.505 5.853 6.718 5.603 7.510 9.398 
17_1 6.630 6.329 6.806 4.826 4.305 4.826 4.482 
18_1 9.432 7.759 6.608 3.975 3.755 7.759 7.409 
19_1 9.542 7.481 6.601 5.449 5.471 6.601 6.788 
20_1 – – – – – – 9.000 
21_1 9.725 9.028 8.771 6.593 6.483 6.483 3.456 
22_1 7.847 6.439 6.212 5.288 5.288 5.288 4.824 
23_1 7.033 6.733 6.256 5.141 5.024 5.024 4.456 
24_1 8.031 6.395 5.948 5.002 5.295 5.002 3.777 
25_1 7.943 6.681 6.505 4.738 5.031 5.031 3.347 
26_1 7.957 6.454 6.197 4.672 4.613 4.613 3.892 
27_1 6.388 5.046 6.168 5.390 5.919 5.046 4.237 
28_1 7.855 6.168 6.271 4.708 4.752 4.708 3.345 
29_1 7.657 6.329 6.425 4.760 4.576 4.576 3.109 
30_1 7.613 6.931 6.579 5.552 5.699 5.552 3.867 
31_1 7.554 7.349 6.586 5.603 4.782 4.782 3.755 
32_1 6.476 5.016 5.765 6.014 5.464 5.016 4.052 
33_1 7.275 6.718 6.300 4.994 4.965 4.965 3.144 
34_1 7.055 6.285 6.036 4.701 4.818 4.701 4.111 
35_1 7.583 6.967 6.395 5.383 5.317 5.317 3.413 
 
a – Compound name + type of binding (depends on the number of phosphonic groups). 
b – 205 compounds without (20, 150, 160). 
c – 202 compounds without outliers (152, 155, 202). 
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3. Results and discussion 
Docking was done by a modified version of 
AutoDock [5].  
This version of AutoDock has several specific 
features, including the ability to impose special 
constraints on docking poses, apply standard 
multidimensional optimization techniques and 
making global optimization by sequential search.  
Positions of the atoms of phosphorous were 
limited to the region around the position of 
phosphorous (or sometimes sulfur) in the original 
PDB files of cluster centroids. We allowed maximal 
deviation of 2 Å.  
New approaches to optimization allow to process 
a large number of molecules in a limited time.  
This Table 2 contains the information about all 
dockings.  
Unfortunately we have found that there is no 
cluster that has good enough correlation with 
experimental results.  
There is also no good correlation between the 
highest and the lowest calculated values and the 
experimental ones (see Figure).  
 
Correaltion between calculated and experimental 
values of pKi 
On the other hand each compound has a variant 
of binding with predicted pKi quiet close to the 
experimental value. 
Furthermore these values correlate with 
experimental values quiet well (R2=0.69, R=0.83, 
RMS = 0.99).  
The best (closest to experimental data) results are 
emphasized by bold characters.  
There are 3 cases when AutoDock failed to 
calculate a reasonable pKi (compounds 20, 150, 
160) or gave the results substantially different from 
experimental (outliers 152, 155, 202) due to some 
limitation of the method (in most cases it was energy 
penalty for too many rotating bonds).  
Correlation without the outliers is substantially 
better (R2=0.76, R=0.88, RMSD = 0.86).  
The best results are not usually the highest or the 
lowest calculated values.  
In general docking tends to overestimate. 
The distribution of the best results over the 
clusters is shown in Table 1. 
These results show that they are more or less 
evenly distributed between clusters and between 
closed (the first three) and open WPD loop 
conformations.  
The authors tried to determine the similarity of 
compounds in each group and similarity of 
compounds from different groups.  
ChemAxon chemical fingerprints were calculated 
by GenerateMD application from the ChemAxon 
package [6].  
The following parameters were used:  
– bit length 1024, maximum number of bits to set 
for each pattern 7; 
– maximal number of bonds 3.  
Similarity of compounds was calculated as 
Tanimoto similarity of the respective bit-strings. 
Mean values were calculated for each cluster and 
for each pair of clusters.  
The results are presented in Table 3. 
Table 3. Similarity of compounds within each cluster and cross-cluster similarity 
Cluster 1Q6M 2CM8 2CNF 1NL9 1PH0 
1Q6M 0,660 0,639 0,623 0,570 0,574 
2CM8 0,639 0,625 0,613 0,564 0,575 
2CNF 0,623 0,613 0,600 0,566 0,572 
1NL9 0,570 0,564 0,566 0,554 0,563 
1PH0 0,574 0,575 0,572 0,563 0,573 
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Unfortunately, the similarity is almost the same 
in all cases. It is not possible to determine from the 
structure which cluster gives the best docking result. 
4. Conlusions 
1. It has been proved that the results of docking 
are heavily dependent on starting conditions.  
The results of dockings into different cluster 
centroids are very different. 
2. It was not possible to find a cluster that gave 
the best docking results for the whole set of 
compounds.  
It all cases the results were rather poor. 
3. Nevertheless, each compound had a simulated 
docking with predicted Ki not very different from 
the experimental result.  
In most cases this was neither the highest nor the 
lowest Ki value.  
Such values gave good correlation between 
experimental and calculated values for the whole set 
of compounds.  
The bindings with the best predicted Ki values 
are probably not feasible due to some kinetic or 
steric reasons. 
4. Unfortunately, it was not possible to explain 
the binding modes of molecules by their structural 
similarity.  
There was no difference between the sets of 
compounds which have the most similar to 
experimental results on different clusters.  
This probably needs further explanation. 
References 
[1] Adams, D.; Abraham, A.; Asano, J.; Breslin, 
C.; Dick, C.; Ixkes, U.; Johnston, B.; Johnston, D.; 
Kewnay, J.; Mackay, S. MacKenzie, S.; McFarlane, 
M.; Mitchell., L.; Spinks, D. Takano, Y. 2-Aryl-
3,3,3-trifluoro-2-hydroxypropionic acids: A new 
class of protein tyrosine phosphatase 1B inhibitors. 
Bioorg. Med. Chem. Lett. 2007. Vol. 17, N 23.  
P. 6579–6583. 
[2] Bernstein, F.; Koetzle, T.; Williams, G.; 
Meyer, E.; Brice, E.; Rodgers, M.; Kennard, O.; 
Shimanouchi, T.; Tasumi, M. The protein data bank: a 
computer based archival file for macromolecular 
structures. J. Mol. Biol. 1977. Vol. 112, N 2. P. 535–542. 
[3] Chen, Y.; Seto, C. Divalent and Trivalent a-
Ketocarboxylic Acids as Inhibitors of Protein 
Tyrosine Phosphatases. J Med Chem. 2002. Vol. 45, 
N 18. P. 3946-3952. 
[4] Craig, I.; Essex, J.; Spiegel, K. Ensemble 
docking into multiple crystallographically derived 
protein structures: An evaluation based on the 
statistical analysis of enrichments. J. Chem. Inf. 
Model. 2010. Vol.50, N 4. P. 511–524. 
[5] http://hpc-ua.org/hpc-ua-13/files/proceedings/76.pdf 
[6] http://www.chemaxon.com 
[7] Hu, X. In silico modeling of protein tyrosine 
phosphatase 1B inhibitors with cellular activity. 
Bioorg. Med. Chem. Lett. 2006. Vol. 16, N 24.  
P. 6321–6327. 
[8] Hu, X.; Vujanac, M.; Stebbins, C. 
Computational analysis of tyrosine phosphatase 
inhibitor selectivity for the virulence factors YopH 
and SptP. J. Mol. Graph Model. 2004. Vol. 23, N 2. 
P. 175–187. 
[9] Kasibhatla, B.; Wos, J.; Peters, K. Targeting 
protein tyrosine phosphatase to enhance insulin 
action for the potential treatment of diabetes. Curr. 
Opin. Invest. Drugs. 2007. Vol. 8, N 10. P. 805-813. 
[10] Koren, S.; Fantus, I.  Inhibition of the 
protein tyrosine phosphatase PTP1B: potential 
therapy for obesity, insulin resistance and type-2 
diabetes mellitus. Best Pract Res. Clin. Endocrinol. 
Metab. 2007. Vol. 21, N 4. P. 621–640. 
[11] Kumar, A.; Ahmad, P.; Maurya, R.; Singh, 
A.; Srivastava, A. Novel 2-aryl-naphtho[1,2-
d]oxazole derivatives as potential PTP-1B inhibitors 
showing antihyperglycemic activities. Eur. J. Med. 
Chem. 2009. Vol. 44, N 1. P. 109–116. 
[12] Lau, C.; Bayly, C.; Gauthier, J.; Li, C.; Therien, M.; 
Asante-Appiah, E.; Cromlish, W.; Boie, Y.; 
Forghani, F.; Desmarais, S.; Wang, Q.; Skorey, K.; 
Waddleton, D.; Payette, P.; Ramachandran, C.; 
Kennedy, B.; Scapin, G. Structure based design of a 
series of potent and selective non peptidic PTP-1B 
inhibitors. Bioorg. Med. Chem. Lett. 2004. Vol. 14, 
N 4. P. 1043–1048. 
[13] Li, X.; Bhandari, A.; Holmes, C.; 
Szardenings, A. α,α-Difluoro-β-ketophosphonates as 
potent inhibitors of protein tyrosine phosphatase 1B. 
Bioorg. Med. Chem. Lett. 2004. Vol. 14, N 16.  
P. 4301–4306. 
[14] Liu, T.; Lin, Y.; Wen, X.; Jorrisen, R.;  
Gilson, M. BindingDB: a web-accessible database of 
experimentally determined protein-ligand binding 
affinities. Nucleic Acids Research. 2007. Vol. 35,    
N Database issue. P. D198–D201. 
[15] Maccari, R.; Paoli, P.; Ottana, R.; 
Jacomelli, M.; Ciurleo, R.; Manao, G.; Steindl, T.; 
Langer, T.; Vigorita, M.; Camici, G. 5-Arylidene-
2,4-thiazolidinediones as inhibitors of protein 
tyrosine phosphatases. Bioorg. Med. Chem. 2007. 
Vol. 15, N 15. P. 5137–5149. 
ISSN 1813-1166 print / ISSN 2306-1472 online. Proceedings of the National Aviation University. 2014. N 3 (60): 87-92 
 
92 
[16] Saxena, A.; Pandey, G.; Gupta, S.; Singh, 
A.; Srivastava A. Synthesis of protein tyrosine 
phosphatase 1B inhibitors: Model validation and 
docking studies. Bioorg. Med. Chem. Lett. 2009.   
Vol. 19, N 8. P. 2320–2323. 
[17] Shim, Y.; Kim, K.; Lee, K.; Shrestha, S.; Lee, 
K.; Kim, C.; Cho, H. Formylchromone derivatives as 
irreversible and selective inhibitors of human protein 
tyrosine phosphatase 1B. Kinetic and modeling 
studies. Bioorg Med Chem. 2005. Vol. 13, N 4.  
P. 1325–1332. 
[18] Shrestha, S.; Bhattarai, B.; Lee, K.; Cho, H. 
Mono- and disalicylic acid derivatives. PTP1B 
inhibitors as potential anti-obesity drugs. Bioorg. 
Med. Chem. 2007. Vol. 15, N 20. P. 6535–6548. 
[19] Tabernero, L.; Aricescu, A.; Jones, E.; 
Szedlacsek, S. Protein tyrosine phosphatases: 
structure–function relationships. FEBS J. 2008.  
Vol. 275, N 5. P. 867–882. 
[20] Tanchuk, V.; Tanin, V.; Vovk, A.  
Classification of binding site conformations of  
rotein tyrosine phosphatase 1B. Chem. Biol. Drug 
Des. 2012. Vol. 80, N 1. P. 121–128. 
[21] Tautz, L.; Mustelin, T. Strategies for 
developing protein tyrosine phosphatase inhibitors. 
Methods. 2007. Vol. 42, N 3. P. 250–260. 
[22] Tonks, N. Protein tyrosine phosphatases: 
From genes, to function, to disease. Nat Rev Mol 
Cell Biol. 2006. Vol. 7, N 11.  P. 833–846. 
[23] Totrov, M.; Abagyan, R. Flexible ligand 
docking to multiple receptor conformations: a 
practical alternative. Curr Opin Struct Biol. 2008. 
Vol. 18, N 2. P. 178–184. 
[24] Vintonyak, V.; Antonchick, A.; Rauh, D.; 
Waldmann, H. The therapeutic potential of 
phosphatase inhibitors. Curr Opin Chem Biol. 2009. 
Vol. 13, N 3. P. 13272–13283. 
[25] Zhang, S.; Zhang, Z. PTP1B as a drug 
target: recent developments in PTP1B inhibitor 
discovery. Drug Discovery Today. 2007. Vol. 12,  
N 9-10. P. 373-381. 
[26] Zhang, Z. Functional studies of protein 
tyrosine phosphatases with chemical approaches. 
Biochim Biophys Acta. 2005. Vol. 1754, N 1–2.  
P. 100–107. 
Received 20 June 2014. 
 
В.О. Танін1, В.Ю. Танчук2. Дослідження типових конформацій протеїнтирозинфосфатази 1B за 
допомогою докінгу 
Інститут біоорганічної хімії та нафтохімії Національної академії наук України, вул.. Мурманська 1, Київ-94, Україна, 
02660 
E-mails: 1vtaninva@gmail.com;  2v_tanchuk@yahoo.com  
За допомогою докінгу відомих інгібіторів досліджено типові конформації протеїнтирозинфосфатази 1B. 
Найкращої конформації не виявлено, хоча для кожного інгібітора існує найбільш відповідна конформація. 
Ключові слова: докінг; кластеризація; конформації; протеїнтирозинфосфатази 1B; сайти зв’язування; 
структурна подібність. 
В.А. Танин1, В.Ю. Танчук2. Исследование типичных конформаций протеинтирозинфосфатазы 1B с 
помощью докинга 
Институт биоорганической химии и нефтехимии Национальной академии наук Украины, ул. Мурманская, 1, Киев-94, 
Украина, 02660 
E-mails: 1vtaninva@gmail.com; 2v_tanchuk@yahoo.com  
С помошью докинга известных ингибиторов исследованы типичные конформации протеинтирозинфосфатазы 
1B. Предпочтительной конформации не найдено, хотя для каждого ингибитора существует наиболее 
подходящая конформация. 
Ключевые слова: докинг; кластеризация; конформации; протеинтирозинфосфатазы 1B; сайты связывания; 
структурное подобие. 
Volodymyr Tanin. Engineer. 
Third Department, Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Sciences of Ukraine,  
Kyiv, Ukraine. 
Education: Faculty of Chemistry, specialty engineer of Organic Chemistry and Technology of Organic Substances,  
National Technical University of Ukraine “Kyiv Polytechnic Institute”, Kyiv, Ukraine (2008). 
Research area:  computer chemistry. 
Publications:  15. 
E-mail: vtaninva@gmail.com 
 
Vsevolod Tanchuk. Candidate of Chemistry. Senior Researcher. 
Third Department, Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Sciences of Ukraine,  
Kyiv, Ukraine. 
Education: Department of Chemistry, specialty - physic chemistry , Kyiv Taras Shevchenko University, Kyiv, Ukraine  (1991).  
Research area: computer chemistry. 
Publications:  100. 
E-mail: v_tanchuk@yahoo.com 
